Business Wire

Pinion Insurance Appoints Gary S. Maier as US CEO

29.9.2026 14:31:00 CEST | Business Wire | Press Release

Share

Pinion Insurance, the London-headquartered specialty insurance carrier established earlier this year, today announced the appointment of Gary S. Maier as US Chief Executive Officer, effective today.

Maier brings nearly four decades of insurance industry experience across underwriting, distribution, MGAs, product development, and corporate development. He will lead Pinion’s US operations and drive the expansion of its specialty insurance platform, which provides capacity to MGAs across the US, UK and European markets.

“Gary’s experience is a strong fit with Pinion’s focus on underwriting excellence, innovation, and close collaboration with MGAs,” said Laura Baird, Pinion Co-Founder and Group Chief Technology Officer. “He is a highly respected industry leader and innovator, and we are delighted to welcome him to the team.”

Maier joins Pinion from Ledger Risk Markets, where he served as CEO, and Ledger Investing, where he was Chief Revenue Officer. At Ledger, he led the development of casualty insurance-linked securities (ILS) platforms, sourcing risk originators and helping build a securitization marketplace that placed more than $2.5 billion in premium during its first several years.

Previously, Maier was Managing Principal at Capacity Group of New Jersey Inc., a retail and wholesale insurance brokerage. From 2005 to 2013, he served as Executive Vice President and Chief Underwriting Officer of Tower Group Inc., overseeing US marketing and distribution, as well as corporate development. He began his career at Chubb, where he spent more than 17 years, rising from trainee to Zone Executive Underwriting Officer.

“Pinion is bringing a new approach to specialty insurance,” said Maier. “Pinion is combining deep underwriting expertise with modern technology and data. It makes the MGA and capacity relationship more transparent, efficient, and responsive. I’m excited to join the team and look forward to building and growing Pinion’s US operations.”

Maier’s appointment comes as Pinion builds momentum following the appointments of US Chief Underwriting Officer, Kyle Selvig, and Group Chief Financial Officer, Chris Jones, earlier this year. The company has also recently launched Sarrus, its upgraded, fully integrated proprietary technology platform designed to modernize data exchange across the MGA sector.

Sarrus provides daily portfolio visibility and audit-ready reporting, addressing what Pinion sees as fragmented and outdated processes across the MGA market.

“Gary brings unique insights, unrivalled experience and a shared vision for Pinion’s profitable growth in the US,” said Philip Vandoninck, Pinion Co-Founder and Group Chief Underwriting Officer. “He is also a proven market maker, an innovator, and we are very pleased to welcome him to Pinion.”

About Pinion Insurance

Pinion Insurance is the strategic partner of choice to Managing General Agents (MGAs) and capital providers. It is a specialty insurance platform that offers capacity for MGAs across the U.S., UK, and European markets through a fully integrated proprietary technology platform.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260929189347/en/

Contacts

Caitlin Haynes
caitlin.haynes@rein4ce.co.uk
+44 (0) 203 131 2474
+44 (0) 7568 572367

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye